Vancomycin-resistant Enterococcus faecium infection in patients with hematologic malignancy: Patients with acute myeloid leukemia are at high-risk

European Journal of Haematology

Volumn 79, Issue 3, 2007, Pages 226-233

  Worth, Leon J ^a,b   Thursky, Karin A ^a,b   Seymour, John F ^a,c   Slavin, Monica A ^a,b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Acute myeloid leukemia; Risk factors; Vancomycin; Vancomycin resistant Enterococcus faecium

Indexed keywords

CARBAPENEM; CARBOPLATIN; CEFEPIME; CEPHALOSPORIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; GENTAMICIN; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; IFOSFAMIDE; MELPHALAN; METRONIDAZOLE; MITOXANTRONE; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RETINOIC ACID; VANCOMYCIN; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; B CELL LYMPHOMA; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE ASSOCIATION; ENTEROCOCCAL INFECTION; EWING SARCOMA; FEMALE; HEMATOLOGIC MALIGNANCY; HIGH RISK POPULATION; HOSPITAL ADMISSION; HUMAN; INFECTION CONTROL; LARGE CELL LYMPHOMA; MALE; MONOTHERAPY; MULTIPLE MYELOMA; NEUTROPENIA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ACUTE DISEASE; ADULT; AGED; CASE-CONTROL STUDIES; DISEASE OUTBREAKS; ENTEROCOCCUS FAECIUM; FEMALE; GRAM-POSITIVE BACTERIAL INFECTIONS; HEMATOLOGIC NEOPLASMS; HUMANS; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RISK FACTORS; VANCOMYCIN; VANCOMYCIN RESISTANCE;

EID: 34547817285     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2007.00911.x     Document Type: Article

References (37)

1. Bell J, Turnidge J, Coombs G, O'Brien F. Emergence and epidemiology of vancomycin-resistant enterococci in Australia. Commun Dis Intell 1998 22 : 249 52.
2. Padiglione AA, Grabsch E, Wolfe R, Gibson K, Grayson ML. The prevalence of fecal colonization with VRE among residents of long-term-care facilities in Melbourne, Australia. Infect Control Hosp Epidemiol 2001 22 : 576 8.
3. Grayson ML, Grabsch EA, Johnson PD, Olden D, Aberline M, Li HY, Hogg G, Abbott M, Kerr PG. Outcome of a screening program for vancomycin-resistant enterococci in a hospital in Victoria. Med J Aust 1999 171 : 133 6.
4. Christiansen KJ, Tibbett PA, Beresford W, et al. Eradication of a large outbreak of a single strain of vanB vancomycin-resistant Enterococcus faecium at a major Australian teaching hospital. Infect Control Hosp Epidemiol 2004 25 : 384 90.
5. Oh HS, Kim EC, Oh MD, Choe KW. Outbreak of vancomycin resistant enterococcus in a hematology/oncology unit in a Korean University Hospital, and risk factors related to patients, staff, hospital care and facilities. Scand J Infect Dis 2004 36 : 790 4.
6. Ostrowsky BE, Trick WE, Sohn AH, Quirk SB, Holt S, Carson LA, Hill BC, Arduino MJ, Kuehnert MJ, Jarvis WR. Control of vancomycin-resistant enterococcus in health care facilities in a region. N Engl J Med 2001 344 : 1427 33.
7. Suntharam N, Lankford MG, Trick WE, Peterson LR, Noskin GA. Risk factors for acquisition of vancomycin-resistant enterococci among hematology-oncology patients. Diagn Microbiol Infect Dis 2002 43 : 183 8.
8. Husni R, Hachem R, Hanna H, Raad I. Risk factors for vancomycin-resistant Enterococcus (VRE) infection in colonized patients with cancer. Infect Control Hosp Epidemiol 2002 23 : 102 3.
9. Zaas AK, Song X, Tucker P, Perl TM. Risk factors for development of vancomycin-resistant enterococcal bloodstream infection in patients with cancer who are colonized with vancomycin-resistant enterococci. Clin Infect Dis 2002 35 : 1139 46.
10. Yoo JH, Lee DG, Choi SM, Choi JH, Shin WS, Kim M, Yong D, Lee K, Min WS, Kim CC. Vancomycin-resistant enterococcal bacteremia in a hematology unit: molecular epidemiology and analysis of clinical course. J Korean Med Sci 2005 20 : 169 76.
11. Kirkpatrick BD, Harrington SM, Smith D, Marcellus D, Miller C, Dick J, Karanfil L, Perl TM. An outbreak of vancomycin-dependent Enterococcus faecium in a bone marrow transplant unit. Clin Infect Dis 1999 29 : 1268 73.
12. Sample ML, Gravel D, Oxley C, Toye B, Garber G, Ramotar K. An outbreak of vancomycin-resistant enterococci in a hematology-oncology unit: control by patient cohorting and terminal cleaning of the environment. Infect Control Hosp Epidemiol 2002 23 : 468 70.
13. Timmers GJ, Van der Zwet WC, Simoons-Smit IM, Savelkoul PH, Meester HH, Vandenbroucke-Grauls CM, Huijgens PC. Outbreak of vancomycin-resistant Enterococcus faecium in a haematology unit: risk factor assessment and successful control of the epidemic. Br J Haematol 2002 116 : 826 33.
14. McCarthy KM, Van Nierop W, Duse A, Von Gottberg A, Kassel M, Perovic O, Smego R. Control of an outbreak of vancomycin-resistant Enterococcus faecium in an oncology ward in South Africa: effective use of limited resources. J Hosp Infect 2000 44 : 294 300.
15. Muto CA, Jernigan JA, Ostrowsky BE, Richet HM, Jarvis WR, Boyce JM, Farr BM. SHEA guideline for preventing nosocomial transmission of multidrug-resistant strains of Staphylococcus aureus and enterococcus. Infect Control Hosp Epidemiol 2003 24 : 362 86.
16. Link H, Bohme A, Cornely OA, et al. Antimicrobial therapy of unexplained fever in neutropenic patients-guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Study Group Interventional Therapy of Unexplained Fever, Arbeitsgemeinschaft Supportivmassnahmen in der Onkologie (ASO) of the Deutsche Krebsgesellschaft (DKG-German Cancer Society). Ann Hematol 2003 82 (Suppl. 2 S105 17.
17. Tenover FC, Arbeit RD, Goering RV, Mickelsen PA, Murray BE, Persing DH, Swaminathan B. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol 1995 33 : 2233 9.
18. Gray LC, Yeo MA, Duckett SJ. Trends in the use of hospital beds by older people in Australia: 1993-2002. Med J Aust 2004 181 : 478 81.
19. Chen S, Slavin M, Nguyen Q, Marriott D, Playford EG, Ellis D, Sorrell T. Active surveillance for candidemia, Australia. Emerg Infect Dis 2006 12 : 1508 16.
20. Wacholder S, Silverman DT, McLaughlin JK, Mandel JS. Selection of controls in case-control studies. III. Design options. Am J Epidemiol 1992 135 : 1042 50.
21. Wacholder S, McLaughlin JK, Silverman DT, Mandel JS. Selection of controls in case-control studies. I. Principles. Am J Epidemiol 1992 135 : 1019 28.
22. Bell JM, Paton JC, Turnidge J. Emergence of vancomycin-resistant enterococci in Australia: phenotypic and genotypic characteristics of isolates. J Clin Microbiol 1998 36 : 2187 90.
23. Avery R, Kalaycio M, Pohlman B, et al. Early vancomycin-resistant enterococcus (VRE) bacteremia after allogeneic bone marrow transplantation is associated with a rapidly deteriorating clinical course. Bone Marrow Transplant 2005 35 : 497 9.
24. Noskin GA, Cooper I, Peterson LR. Vancomycin-resistant Enterococcus faecium sepsis following persistent colonization. Arch Intern Med 1995 155 : 1445 7.
25. Koc Y, Snydman DR, Schenkein DS, Miller KB. Vancomycin-resistant enterococcal infections in bone marrow transplant recipients. Bone Marrow Transplant 1998 22 : 207 9.
26. Bach PB, Malak SF, Jurcic J, Gelfand SE, Eagan J, Little C, Sepkowitz KA. Impact of infection by vancomycin-resistant Enterococcus on survival and resource utilization for patients with leukemia. Infect Control Hosp Epidemiol 2002 23 : 471 4.
27. DiazGranados CA, Jernigan JA. Impact of vancomycin resistance on mortality among patients with neutropenia and enterococcal bloodstream infection. J Infect Dis 2005 191 : 588 95.
28. Edmond MB, Ober JF, Dawson JD, Weinbaum DL, Wenzel RP. Vancomycin-resistant enterococcal bacteremia: natural history and attributable mortality. Clin Infect Dis 1996 23 : 1234 9.
29. Matar MJ, Safdar A, Rolston KV. Relationship of colonization with vancomycin-resistant enterococci and risk of systemic infection in patients with cancer. Clin Infect Dis 2006 42 : 1506 7.
30. Patel R. Clinical impact of vancomycin-resistant enterococci. J Antimicrob Chemother 2003 51 (Suppl. 3 iii13 21.
31. Lautenbach E, Bilker WB, Brennan PJ. Enterococcal bacteremia: risk factors for vancomycin resistance and predictors of mortality. Infect Control Hosp Epidemiol 1999 20 : 318 23.
32. Shay DK, Maloney SA, Montecalvo M, Banerjee S, Wormser GP, Arduino MJ, Bland LA, Jarvis WR. Epidemiology and mortality risk of vancomycin-resistant enterococcal bloodstream infections. J Infect Dis 1995 172 : 993 1000.
33. Padiglione AA, Wolfe R, Grabsch EA, Olden D, Pearson S, Franklin C, Spelman D, Mayall B, Johnson PD, Grayson ML. Risk factors for new detection of vancomycin-resistant enterococci in acute-care hospitals that employ strict infection control procedures. Antimicrob Agents Chemother 2003 47 : 2492 8.
34. Lucas GM, Lechtzin N, Puryear DW, Yau LL, Flexner CW, Moore RD. Vancomycin-resistant and vancomycin-susceptible enterococcal bacteremia: comparison of clinical features and outcomes. Clin Infect Dis 1998 26 : 1127 33.
35. Chavers LS, Moser SA, Funkhouser E, Benjamin WH Jr., Chavers P, Stamm AM, Waites KB. Association between antecedent intravenous antimicrobial exposure and isolation of vancomycin-resistant enterococci. Microb Drug Resist 2003 9 (Suppl. 1 S69 77.
36. Kuehnert MJ, Jernigan JA, Pullen AL, Rimland D, Jarvis WR. Association between mucositis severity and vancomycin-resistant enterococcal bloodstream infection in hospitalized cancer patients. Infect Control Hosp Epidemiol 1999 20 : 660 3.
37. Padiglione AA, Grabsch EA, Olden D, Hellard M, Sinclair MI, Fairley CK, Grayson ML. Fecal colonization with vancomycin-resistant enterococci in Australia. Emerg Infect Dis 2000 6 : 534 6.